找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Breast Disease; Management and Thera Adnan Aydiner,Abdullah Igci,Atilla Soran Book 2019Latest edition Springer Nature Switzerland AG 2019 b

[复制链接]
楼主: Weber-test
发表于 2025-3-30 10:52:08 | 显示全部楼层
Rui Liu,Feilong Bao,Guanglai Gao,Yonghe Wange “oncoplastic breast surgery (OBS)” concept has come into consideration among breast surgeons in the last two decades. The aim of OBS is to make no compromise from oncologic principles for a better cosmetic result. The tumor cavity is filled with the remaining breast tissue (volume displacement tec
发表于 2025-3-30 15:27:56 | 显示全部楼层
Research on Telegrapher Selectionaxilla can become negative in up to 60% of cases depending on tumor biology, and SLNB can be performed with a low false-negative rate either using the targeted (clip-seed) technique or in the classic fashion (lympho-blue dye). In patients with positive SLNB (with limited involvement) after neoadjuva
发表于 2025-3-30 16:53:28 | 显示全部楼层
Haijing Song,Li Han,Hongjiao Wus with tamoxifen in premenopausal and postmenopausal women, lowering systemic estrogen levels with luteinizing hormone-releasing hormone agonists in premenopausal women, or blocking estrogen biosynthesis in nonovarian tissues with aromatase inhibitors in postmenopausal women.
发表于 2025-3-30 21:23:34 | 显示全部楼层
Man-Machine-Environment System Engineeringgimen depends on the intrinsic subtype. Multigene expression array profiling is not always required for subtype definition after clinicopathological assessment. Young age, grade 3 disease, lymphovascular invasion, one to three positive nodes, and large tumor size are not adequate features to omit mo
发表于 2025-3-31 03:54:01 | 显示全部楼层
Shengzhao Long,Balbir S. Dhillonnts with HER-2-positive early breast cancer. Thus, the monoclonal antibody trastuzumab has been approved as the first and only molecularly targeted agent for the adjuvant treatment of HER-2-positive breast cancer. Despite tremendous progress in the treatment of HER-2-positive breast cancer, many que
发表于 2025-3-31 09:02:19 | 显示全部楼层
发表于 2025-3-31 12:41:48 | 显示全部楼层
Chenming Li,Tianhao Wang,Yuhong ShenC provides an ideal setting in which the responsiveness of a given treatment can be observed and provides relevant information on the biology of the tumor by enabling biomarker analysis. Accumulating data on the strong association with survival and pathological complete response (pCR) may lead to a
发表于 2025-3-31 16:14:16 | 显示全部楼层
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-6-26 01:13
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表